Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors

BACKGROUND: The mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumours (PNETs). However, adaptive resistance to mTOR inhibition is described. METHODS: QGP-1 and BON-1, two human PNET cell lines, were cultured with increasing concentrations of evero...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Principais autores: Vandamme, Timon, Beyens, Matthias, de Beeck, Ken Op, Dogan, Fadime, van Koetsveld, Peter M, Pauwels, Patrick, Mortier, Geert, Vangestel, Christel, de Herder, Wouter, Van Camp, Guy, Peeters, Marc, Hofland, Leo J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800296/
https://ncbi.nlm.nih.gov/pubmed/26978006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.25
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados